Compared with the parent compound [[rapamycin]], everolimus is more selective for the [[mTORC1]] protein complex, with little impact on the [[mTORC2]] complex.<ref name=ArriolaApelo>{{Cite journal|title = Alternative rapamycin treatment regimens mitigate the impact of rapamycin on glucose homeostasis and the immune system|journal = Aging Cell|date = 2015-10-13|issn = 1474-9726|pmid = 26463117|doi = 10.1111/acel.12405|first = Sebastian I.|last = Arriola Apelo|first2 = Joshua C.|last2 = Neuman|first3 = Emma L.|last3 = Baar|first4 = Faizan A.|last4 = Syed|first5 = Nicole E.|last5 = Cummings|first6 = Harpreet K.|last6 = Brar|first7 = Cassidy P.|last7 = Pumper|first8 = Michelle E.|last8 = Kimple|first9 = Dudley W.|last9 = Lamming|volume=15|pmc=4717280|pages=28–38}}</ref> This can lead to a hyper-activation of the kinase [[AKT]] via inhibition on the mTORC1 negative feedback loop, while not inhibiting the mTORC2 positive feedback to AKT. This AKT elevation can lead to longer survival in some cell types. Thus, everolimus has important effects on cell growth, cell proliferation and cell survival.

 
Inhibition of [[Mechanistic target of rapamycin|mTOR]], the molecular target of everolimus, extends the lifespan of model organisms including mice,<ref>{{Cite journal|title = Rapamycin fed late in life extends lifespan in genetically heterogeneous mice|journal = Nature|date = 2009-07-16|issn = 1476-4687|pmc = 2786175|pmid = 19587680|pages = 392–395|volume = 460|issue = 7253|doi = 10.1038/nature08221|first = David E.|last = Harrison|first2 = Randy|last2 = Strong|first3 = Zelton Dave|last3 = Sharp|first4 = James F.|last4 = Nelson|first5 = Clinton M.|last5 = Astle|first6 = Kevin|last6 = Flurkey|first7 = Nancy L.|last7 = Nadon|first8 = J. Erby|last8 = Wilkinson|first9 = Krystyna|last9 = Frenkel}}</ref> and mTOR inhibition has been suggested as an anti-aging therapy. Everolimus was used in a recent clinical trial by Novartis, and short-term treatment was shown to enhance the response to the influenza vaccine in the elderly, possible by reversing [[immunosenescence]].<ref>{{Cite journal|title = mTOR inhibition improves immune function in the elderly|url = http://www.ncbi.nlm.nih.gov/pubmed/?term=25540326|journal = Science Translational Medicine|date = 2014-12-24|issn = 1946-6242|pmid = 25540326|pages = 268ra179|volume = 6|issue = 268|doi = 10.1126/scitranslmed.3009892|first = Joan B.|last = Mannick|first2 = Giuseppe|last2 = Del Giudice|first3 = Maria|last3 = Lattanzi|first4 = Nicholas M.|last4 = Valiante|first5 = Jens|last5 = Praestgaard|first6 = Baisong|last6 = Huang|first7 = Michael A.|last7 = Lonetto|first8 = Holden T.|last8 = Maecker|first9 = John|last9 = Kovarik}}</ref> Everolimus treatment of mice results in reduced metabolic side effects compared to [[sirolimus]].<ref name=ArriolaApelo/>
